Evopoint Biosciences

Evopoint Biosciences was founded in 2017 as a platform-based innovative drug company with both strong research capabilities and commercialization capacity. Based on three self-developed technology platforms—targeted therapy, anti-infectives, and PROTAC—Evopoint Biosciences has built a pipeline of innovative drugs, including BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and next-generation ADCs, covering disease areas such as oncology, anti-infectives, and metabolic disorders. Currently, the company has multiple products in clinical development stages. Supported by excellent product data and out-licensing capabilities, Evopoint Biosciences has reached several out-licensing collaborations with well-known companies domestically and internationally, with a total value of billions of US dollars. Since its establishment, Evopoint Biosciences has been committed to improving human health, focusing on providing high-quality solutions for significant unmet clinical needs worldwide.